The applicant will thoroughly characterize the murine mucosal and systemic responses (cellular and humoral) generated by immunization with HIV envelope protein, and the effectiveness of IL-12 as an adjuvant for the production of immunity at mucosal surfaces will also be examined.
In Aim 1, the ability to enhance mucosal immunity by co-administering recombinant IL-12 with HIV gp160 via the oral and intranasal route will be assessed.
In Aim 2, DNA IL-12 will be delivered either mucosally or remotely by IM or gene gun, and similar characterizations of immune responses will be performed.
In Aim 3, experiments will examine the potential dysregulation of mucosal immune responses by immunization with rgp160 in combination with IL-12 protein or the plasmid DNA-IL-12.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI043278-04
Application #
6163950
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Program Officer
Bradac, James A
Project Start
1998-03-01
Project End
2003-02-28
Budget Start
2000-03-01
Budget End
2001-02-28
Support Year
4
Fiscal Year
2000
Total Cost
$98,956
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163